OakChart

Grifols SA ADR

GRFSHealthcare·Drug Manufacturers - General·Spain·Mid·NASD·Nov 11 • 12:05 PM ET

8.77+0.01 (0.06%)
2026-11-11 18:06 CET
Market cap
2,262.04 USD m
Revenue, TTM
8,821.37 USD m
Net income, TTM
565.20 USD m
Free cash flow, TTM
977.56 USD m
EPS diluted, TTM
0.83
P/E
10.55
Compare

Price

GRFS against its 20, 50 and 200-day averages
2050200beatmiss
7.007.508.008.509.002.0M4.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GRFSclose 8.7720-day 8.1050-day 7.71200-day 7.988.7752w low

10.3% under the 52-week high of 9.77 on 18 Feb 2026. 52-week low 6.96 on 1 Jul 2026. Last 15 sessions, 19.6% high to low

Profile

GRFS
52-week range, 64% of the way up
6.969.77

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by Jose Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.

Employees25258
IPOJun 02, 2011
Beta0.71
ATR, 14d0.24
Rel volume1.30
Short float2.32%
Insider own0.06%
Inst own56.61%

Snapshot

6 groups

Valuation

Index-
Market Cap2.26B
Enterprise Value15.00B
Income565.20M
Sales8.82B
Book/sh9.66
Cash/sh2.14
Dividend Est.0.26 (2.98%)
Dividend TTM0.11 (1.21%)
Dividend Ex-DateDec 03, 2026
Dividend Gr. 3/5Y- -8.05%
Payout34.22%
Employees25258
IPOJun 02, 2011

Ratios

P/E10.55
Forward P/E7.31
PEG0.33
P/S0.26
P/B0.91
P/C4.10
P/FCF2.32
EV/EBITDA7.60
EV/Sales1.70
Quick Ratio0.82
Current Ratio2.33
Debt/Eq1.60
LT Debt/Eq1.50
Option/ShortYes / Yes

Earnings

EPS (ttm)0.83
EPS next Y1.20
EPS next Q-
EPS this Y14.50%
EPS next Y22.76%
EPS next 5Y22.10%
EPS past 3/5Y27.36% -8.34%
Sales past 3/5Y10.04% 6.88%
EPS Y/Y TTM61.67%
Sales Y/Y TTM6.15%
EPS Q/Q25.47%
Sales Q/Q7.67%
EarningsNov 02 AMC
EPS/Sales Surpr.0.00% 3.48%

Ownership

Insider Own0.06%
Insider Trans0.00%
Inst Own56.61%
Inst Trans3.96%
ROA2.44%
ROE8.93%
ROIC3.44%
Gross Margin37.09%
Oper. Margin16.40%
Profit Margin6.41%
SMA208.25%
SMA5013.71%
SMA2009.83%
Trades-

Technical

Shs Outstand258.22M
Shs Float258.07M
Short Float2.32%
Short Ratio10.05
Short Interest5.98M
52W High9.77 -10.29%
52W Low6.96 25.93%
Volatility3.35% 2.87%
ATR (14)0.24
RSI (14)74.00
Beta0.71
Rel Volume1.30
Avg Volume594.83K
Volume331,961

Performance

Perf Week1.80%
Perf Month22.25%
Perf Quarter10.53%
Perf Half Y13.68%
Perf YTD-6.26%
Perf Year0.40%
Perf 3Y-1.63%
Perf 5Y-27.26%
Perf 10Y-44.31%
Recom2.60
Target Price11.30
Prev Close8.76
Price8.77
Change %0.06%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Feb 12, 2025ResumedMMorgan StanleyOverweight
Mar 12, 2024DowngradeDDeutsche BankHold → Sell
Apr 12, 2023UpgradeMMorgan StanleyEqual-Weight → Overweight
Mar 03, 2023DowngradeMMorgan StanleyOverweight → Equal-Weight
Feb 16, 2023UpgradeBBarclaysUnderweight → Equal Weight
Jan 18, 2023UpgradeJJefferiesHold → Buy
Apr 08, 2022InitiatedMMorgan StanleyEqual-Weight
Nov 05, 2021DowngradeDDeutsche BankBuy → Hold
Oct 19, 2021DowngradeBBarclaysOverweight → Underweight
Oct 06, 2021UpgradeCCitigroupNeutral → Buy

Peers

Mkt cap
TickerCompanyMkt cap
ADMAAdma Biologics Inc2.88B
TAKTakeda Pharmaceutical Co ADR66.20B
HAEHaemonetics Corp5.52B
KMDAKamada Ltd466.14M
ARGXArgen X SE ADR61.39B
QDELQuidelOrtho Corp830.56M
SNYSanofi ADR114.29B
GSKGSK Plc ADR100.44B
CERSCerus Corp429.15M
IMVTImmunovant Inc7.65B

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
BINVBrandes International ETFAUM: 580.22M
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
BSMCBrandes U.S. Small-Mid Cap Value ETFAUM: 175.59M
SPDWState Street SPDR Portfolio Developed World ex-US ETFAUM: 41.64B
CGICCapital Group International Core Equity ETFAUM: 2.57B
APIEActivePassive International Equity ETFAUM: 1.13B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
AVNCAvantis All International Core Equity ETFAUM: 98.25M

News

latest 14 of 206
  • Grifols Beats Q3 Revenue Forecasts as Immunoglobulin Demand Supports Profit Growth (InvestorsHub)
  • Grifols Q3 revenue exceeds estimates as immunoglobulin sales drive growth (Investing.com) +5.06%
  • Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
  • Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ... (GuruFocus.com)
  • Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins (GlobeNewswire)
  • Loading…
  • Grifols Launches FESILTY (fibrinogen, human-chmt) in the U.S. (GlobeNewswire)
  • Grifols shares slide 4% as margin miss soured Q1 profit jump (Investing.com)
  • Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease (GlobeNewswire)
  • Grifols slides as Morgan Stanley downgrades on uncertain growth outlook (Investing.com) -6.39%
  • Grifols SA (GRFS) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
  • ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? (Zacks)
  • Down 10.4% in 4 Weeks, Here's Why Grifols (GRFS) Looks Ripe for a Turnaround (Zacks)
  • Grifols SA (GRFS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ... (GuruFocus.com) -6.40%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-020.3200.3200.2742,2892,2122
2026Q22026-07-280.2510.2640.2632,1332,1662
2026Q12026-05-070.1730.1610.1262,0022,0312
2025Q42026-02-260.2890.2960.1682,3402,3452
2025Q32025-11-040.2110.2420.2182,1412,1532
2025Q22025-07-290.2230.2260.1952,1792,1982
2025Q12025-05-120.1330.1490.0921,9931,9612
2024Q42025-02-260.2370.2320.1082,0582,0343
2024Q32024-11-070.1730.2160.0841,9391,9123
2024Q22024-07-300.0870.1460.0241,9671,9474
2024Q12024-05-140.0850.1060.0341,7651,7493
2023Q32023-11-020.1500.2040.0961,5801,6833
2023Q22023-07-270.1650.1990.0841,8281,8553
2023Q12023-05-090.044--0.0171,690-2
2022S12022-07-270.2130.2930.2142,8542,8031
2026Q4--0.331--2,3131

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.1491.1181.0215,6015,573
2020FY1.3011.2221.0306,4826,492
2021FY0.4950.8040.3295,5415,831
2022FY0.5590.5110.3236,4316,331
2023FY0.3710.4520.0677,1347,168
2024FY0.7320.6110.2507,5107,488
2025FY0.8180.8500.6898,8848,816
2026FY-0.976--8,614
2027FY-1.199--9,162
2028FY-1.552--9,669
2029FY-1.682--10,334
2030FY-1.878--10,731

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-031012,3132,3132,313
2026Q4S2026-11-021102,4192,4192,419
2026Q4S2026-09-041102,4192,4192,419
2026Q4S2026-07-291012,3702,3702,370
2026Q4S2026-05-081002,4302,4302,430
2026Q4S2026-04-081102,4422,4422,442
2026Q4S2026-04-021002,4122,4122,412
2026Q4R2026-11-031010.300.300.30
2026Q4R2026-11-021100.350.350.35
2026Q4R2026-09-041100.350.350.35
2026Q4R2026-07-291100.330.330.33
2026Q4R2026-07-221000.290.290.29
2026Q4R2026-05-081010.290.290.29
2026Q4R2026-04-081100.330.330.33

Estimate history

EPS, annual1.1051.0281.0211.030.3290.3230.0670.250.6670.8305
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0840.1080.0920.1950.2180.1680.1260.2630.274
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual4920.8335293.2125706.7036087.5075830.8516373.0747126.6897801.5678491.4218821.37
Period201720182019202020212022202320242025TTM
Sales, quarterly1969.6432107.5851879.4982143.5072179.9562306.5181988.8772178.9182347.06
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual261.425257.607258.01258.413256.355256.225256.907258.224258.224258.224
Period201720182019202020212022202320242025MRQ
Shares, quarterly256.907258.224258.224257.444257.444258.224258.224258.224258.224
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue8,821.378,491.427,801.577,126.696,373.075,830.856,087.515,706.705,293.21
Cost of Goods Sold Incl. D&A5,549.565,460.064,956.784,627.574,166.893,686.143,657.153,208.702,972.08
Gross Profit3,271.813,031.362,844.792,499.122,206.182,144.712,430.362,498.002,321.14
Selling, General and Administrative Excl. Other1,824.801,620.641,595.211,725.541,485.561,485.511,318.501,241.771,148.32
Research and Development464.54420.96357.74357.36333.00354.09297.99283.78260.52
Other Operating Expense0.0015.8033.3027.020.000.000.000.000.00
Operating Income1,447.001,394.921,216.28746.56720.62659.201,111.851,256.241,172.82
Interest Expense616.72705.36773.15645.30521.83328.58284.58383.86345.99
Unusual Expense0.00-33.86-11.68-1.58-6.6213.30-63.5040.670.00
Net Income Before Taxes829.80703.10440.46155.90272.48336.52909.32948.75869.33
Income Taxes150.99129.79250.0846.8794.70100.62193.38188.55155.06
Consolidated Net Income670.36564.29230.19176.95284.97313.61808.23725.99701.25
Net Income From Continuing Operations565.20453.69169.7445.75218.90223.07705.13699.69703.89
Net Income565.20453.69169.7445.75218.90223.07705.13699.69703.89
EPS (Recurring)0.830.630.240.070.320.340.971.061.03
EPS (Basic, Before Extraordinaries)0.830.670.250.070.320.331.031.021.03
EPS (Diluted)0.830.670.250.070.320.331.031.021.03
EBITDA1,973.661,902.781,689.951,229.191,149.271,084.441,478.391,594.761,442.52
Non-Operating Income (Expense)0.66-20.31-14.3653.0767.0719.2118.54117.0542.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Price To Earnings Ratio11.3011.3029.671,651.4397.2534.3017.7422.8017.78
Price To Sales Ratio0.560.750.651.100.901.312.072.802.37
Gross Margin37.0935.7036.4635.0734.6236.7839.9243.7743.85
Operating Margin16.4016.4315.5910.4811.3111.3118.2622.0122.16
Net Margin6.415.342.180.643.433.8311.5812.2613.30
Shares Outstanding258.22258.22258.22256.91256.23256.35258.41258.01257.61
Market Capitalization2,262.042,262.041,915.382,964.902,182.162,878.864,765.086,008.944,726.76

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue2,347.062,178.921,988.882,306.522,179.962,143.511,879.502,107.58
Cost of Goods Sold Incl. D&A1,418.591,360.371,263.521,507.081,322.541,333.141,148.391,289.97
Gross Profit928.47818.55725.36799.44857.42810.37731.11817.61
Selling, General and Administrative Excl. Other475.16436.02434.04479.58446.43414.18442.77410.12
Research and Development100.1099.99105.29159.15113.3893.69101.08122.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income453.30382.53291.31319.86410.99396.19288.34407.49
Interest Expense176.0391.85162.62186.22182.39180.52161.65172.08
Unusual Expense0.000.000.000.000.00-29.380.000.00
Net Income Before Taxes276.12290.68128.69134.30229.10216.71126.69235.41
Income Taxes65.5874.4128.08-17.0863.9359.0824.04135.21
Consolidated Net Income208.24212.78102.95146.39167.61156.8597.2789.37
Net Income From Continuing Operations186.38179.0685.40114.36148.37132.6962.8673.57
Net Income186.38179.0685.40114.36148.37132.6962.8673.57
EPS (Recurring)0.270.260.130.170.220.160.090.11
EPS (Basic, Before Extraordinaries)0.270.260.130.170.220.200.090.11
EPS (Diluted)0.270.260.130.170.220.200.090.11
EBITDA584.46506.94412.98469.27531.18506.10405.96524.97
Non-Operating Income (Expense)0.000.000.000.660.50-28.330.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Earnings Ratio11.3010.0111.9015.2320.7729.3928.3529.67
Price To Sales Ratio0.560.560.630.750.810.760.610.65
Gross Margin39.5637.5736.4734.6639.3337.8138.9038.79
Operating Margin19.3117.5614.6513.8718.8518.4815.3419.33
Net Margin7.948.224.294.966.816.193.343.49
Shares Outstanding258.22258.22258.22258.22257.44257.44258.22258.22
Market Capitalization2,262.041,828.232,070.962,407.102,564.142,334.341,835.971,915.38

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments968.921,014.56585.00584.83745.43709.232,759.911,181.781,064.53
Short Term Receivables992.41896.73895.72805.58563.46616.91528.13459.06462.63
Inventories3,870.993,686.483,846.833,416.652,569.342,449.892,629.562,228.411,956.46
Other Current Assets126.84333.101,445.08159.482,388.0796.45101.45112.6353.12
Total Current Assets5,959.165,930.876,772.634,966.546,266.293,872.486,019.053,981.883,536.74
Net Property, Plant & Equipment4,758.874,463.164,631.094,448.823,801.833,674.083,214.172,231.412,113.47
Total Investments and Advances540.25548.97500.342,636.222,575.962,422.70161.62261.58341.12
Long-Term Note Receivable156.2020.68150.92103.03101.3398.93116.72114.45-
Intangible Assets11,228.9210,695.8710,642.5510,630.948,945.058,430.167,790.827,538.817,036.50
Deferred Tax Assets542.60365.92346.80322.59261.94183.44138.09128.6579.44
Other Assets18.79151.76159.639.908.837.676.106.365.79
Total Assets23,204.7822,177.2523,203.9723,118.0421,961.2218,689.4517,446.5814,263.1413,113.05
Short Term Debt Incl. Current Port. of LT Debt453.34539.54961.54727.092,722.66391.01358.69298.50159.79
Accounts Payable987.71882.56909.08781.14715.29736.11653.16642.32508.05
Income Tax Payable29.3662.6816.0416.745.144.266.702.198.06
Other Current Liabilities900.80747.90682.14562.41507.90502.23515.41494.30498.47
Total Current Liabilities2,371.212,232.692,568.802,087.383,950.991,633.611,533.961,437.311,174.37
Long Term Debt9,816.058,988.4110,184.359,678.737,880.948,065.437,617.386,882.347,058.52
Provision for Risks Charges139.76129.49129.16117.4627.4333.379.016.996.92
Deferred Tax Liabilities1,065.231,059.741,107.131,240.32809.47681.29520.65462.29467.01
Other Liabilities864.40839.90899.27951.69954.2932.6268.4391.7428.38
Total Liabilities14,256.6513,250.2314,888.7114,075.5913,623.1210,446.329,749.448,880.678,735.19
Non-Equity Reserves18.7914.4415.2516.1417.1020.8112.7713.5414.20
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6,190.536,092.605,930.186,542.186,281.456,250.375,412.834,830.444,357.80
Total Shareholders Equity6,190.536,092.605,930.186,542.186,281.456,250.375,412.834,830.444,357.80
Accumulated Minority Interest2,738.822,819.982,369.832,484.142,039.561,971.952,271.55538.485.87
Total Equity8,929.348,912.578,300.009,026.318,321.008,222.327,684.375,368.924,363.67
Total Liabilities & Stockholders Equity23,204.7822,177.2523,203.9723,118.0421,961.2218,689.4517,446.5814,263.1413,113.05
Book Value Per Share9.108.958.7325.539.269.137.917.066.27
Tangible Book Value Per Share-19.51-17.83-18.34-15.96-10.39-8.44-9.22-10.51-10.25
Full-Time Employees25,25823,83323,74426,32623,24523,66824,01621,24318,309
Price to Book Ratio0.940.841.210.871.102.022.942.603.69
Return on Assets2.000.740.200.971.103.904.415.146.35
Return on Equity7.392.710.733.413.5612.0913.6615.3218.24
Return on Invested Capital2.831.130.281.351.584.935.376.016.62
Quick Ratio0.881.011.140.740.940.872.211.221.35
Current Ratio2.512.662.642.381.592.373.922.773.01

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income807.93694.08480.27223.81379.67414.231,001.61914.54856.31
Depreciation524.11507.86473.67482.63428.65425.24366.54338.52269.70
Other Funds (Non Cash)27.997.909.29-92.99-167.6148.30-211.05-69.97-119.20
Funds from Operations1,360.041,209.84963.23613.46640.72887.771,157.101,183.091,006.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-70.52-28.2112.64-377.03-640.87-168.62120.23-541.31-133.22
Cash from Operating Activities1,289.521,181.62975.87236.43-0.16719.141,277.33641.78873.59
Capital Expenditures-524.65-477.39-401.70-335.49-394.70-372.43-413.31-461.47-363.03
Net Assets From Acquisitions-51.41-121.89-309.23-31.86-1,611.42-613.60-534.18-134.04-618.28
Sale of Fixed Assets and Businesses4.534.5125.4225.1399.4824.870.313.030.65
Purchase or Sale of Investments-58.91-58.69-47.43-84.51-173.05-48.43-31.05-21.770.00
Purchase of Investments-64.58-64.33-47.43-100.88-173.05-50.19-31.05-21.770.00
Sale Or Maturity of Investments5.665.640.0016.360.001.760.000.00-
Other Uses5.270.000.000.000.000.000.000.00-24.46
Other Sources-0.001,692.040.000.000.000.000.0082.72
Cash from Investing Activities-625.18-653.45959.10-426.74-2,079.69-1,009.59-978.23-614.25-922.41
Cash Dividends Paid-99.41-144.46-1.040.00-0.62-306.07-129.08-267.21-328.96
Change in Capital Stock-150.05-145.590.000.00-3.64-148.580.000.000.00
Repurchase of Common Pref Stock-146.15-145.590.000.00-3.64-148.580.000.000.00
Sale of Common Pref Stock-3.900.000.000.000.000.000.000.000.00
Proceedsfrom Stock Options-3.900.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net--214.43-1,404.45309.67-76.813,343.91-277.44-8.4144.14
Change in Long Term Debt-------0.000.00
Issuance of Long Term Debt-------0.000.00
Reduction of Long Term Debt-------0.000.00
Net Financing Active Other Cash Flow136.7441.7656.381.57-2.93-89.24-9.07-101.35461.13
Other Financing Activities Uses94.820.000.000.00-2.93-92.39-10.52-101.350.00
Cash from Financing Activities-857.66-597.02-1,469.71185.40-193.602,702.28-415.58-376.97176.31
Exchange Rate Effect25.56-106.0921.72-16.3237.3665.55-68.5822.8346.25
Net Change in Cash-166.60-174.93486.98-21.22-2,236.092,477.39-185.06-326.61173.74
Free Cash Flow977.56882.55724.33-6.21-280.23426.75957.96294.38599.91
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow5.678.627.00--63.1415.23587.1946.40
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments552.02586.51808.84968.92729.63655.82
Short Term Receivables1,225.581,168.451,103.81992.411,288.421,198.66
Inventories3,940.263,992.403,984.313,870.993,934.343,928.72
Other Current Assets353.25317.84156.70126.84332.42375.06
Total Current Assets6,071.126,065.216,053.665,959.166,284.816,158.26
Net Property, Plant & Equipment3,619.954,637.223,644.414,758.873,653.624,738.08
Total Investments and Advances544.07459.61701.69540.25583.62552.89
Intangible Assets12,261.5011,228.3512,240.9711,228.9212,353.3311,267.41
Deferred Tax Assets-544.21-542.60-449.63
Other Assets537.2620.58493.1418.79452.7912.30
Total Assets23,036.1722,968.9023,133.8723,204.7823,328.1823,203.68
Short Term Debt Incl. Current Port. of LT Debt621.31480.19678.65453.34699.26610.70
Accounts Payable0.001,144.440.00987.710.001,031.44
Income Tax Payable-105.18-29.36-101.03
Other Current Liabilities1,985.47826.611,768.63900.801,832.69592.97
Total Current Liabilities2,606.782,556.422,447.272,371.212,531.952,336.14
Long Term Debt9,873.949,257.3010,461.989,816.0510,684.059,890.24
Provision for Risks Charges0.00138.340.00139.760.00143.26
Deferred Tax Liabilities-1,058.70-1,065.23-1,082.61
Other Liabilities1,192.64816.321,183.31864.401,243.32813.57
Total Liabilities13,673.3613,827.0714,092.5614,256.6514,459.3214,265.81
Non-Equity Reserves0.0018.290.0018.790.0018.78
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6,574.306,340.746,288.716,190.536,085.266,067.72
Total Shareholders Equity6,574.306,340.746,288.716,190.536,085.266,067.72
Accumulated Minority Interest2,788.512,782.792,752.612,738.822,783.592,851.37
Total Equity9,362.819,123.539,041.318,929.348,868.858,919.09
Total Liabilities & Stockholders Equity23,036.1722,968.9023,133.8723,204.7823,328.1823,203.68
Book Value Per Share9.669.329.249.108.958.93
Tangible Book Value Per Share-22.02-18.93-23.05-19.51-24.35-20.20
Full-Time Employees---25,258--
Price to Book Ratio0.940.770.881.041.121.01
Return on Assets2.442.282.102.021.821.38
Return on Equity8.938.507.777.466.935.40
Return on Invested Capital1.131.150.510.710.880.83
Quick Ratio0.820.810.850.880.930.95
Current Ratio2.332.372.472.512.482.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income33.71334.3685.40354.47150.21129.25
Depreciation130.01125.04121.67147.38124.74120.16
Other Funds (Non Cash)260.62-77.2046.80-202.23152.13-38.80
Funds from Operations424.34382.20253.87299.62427.08210.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-20.74-116.85-125.18192.26-48.66-37.22
Cash from Operating Activities403.60265.35128.69491.88378.43173.38
Capital Expenditures-126.54-139.08-105.29-153.74-127.46-105.84
Net Assets From Acquisitions-14.95-7.00-22.23-7.23-4.13-8.99
Sale of Fixed Assets and Businesses-3.513.510.004.53111.00-111.00
Purchase or Sale of Investments24.55-24.550.00-58.910.000.00
Purchase of Investments24.55-24.550.00-64.580.000.00
Sale Or Maturity of Investments0.000.000.005.660.000.00
Other Uses-36.0510.53-10.5341.31-18.99-8.97
Other Sources0.00--0.000.00-
Cash from Investing Activities-156.49-156.60-138.05-174.03-150.58-123.80
Cash Dividends Paid-69.760.000.00-29.65-115.370.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.00-150.053.900.00
Repurchase of Common Pref Stock0.000.000.00-146.150.000.00
Sale of Common Pref Stock0.000.000.00-3.903.900.00
Proceedsfrom Stock Options0.000.000.00-3.903.900.00
Issuance or Reduction of Debt, Net-274.39-282.88-136.8884.03-56.21-81.46
Net Financing Active Other Cash Flow-5.8115.21-15.21142.55-1.43-120.26
Other Financing Activities Uses-5.8115.21-15.21100.632.33-102.97
Cash from Financing Activities-279.82-337.83-152.09-87.93-169.10-201.72
Exchange Rate Effect1.028.1717.55-1.19-5.61-66.64
Net Change in Cash-30.52-220.91-143.90228.7353.14-218.77
Free Cash Flow327.63188.2167.86393.86295.07106.22
Price to Free Cash Flow5.676.027.608.598.176.79

Revenue breakdown

Bio supplies2024: 233.70M 2025: 173.70M
Haemoderivatives2024: 6.65B 2025: 7.32B
Other Product2024: 225.05M 2025: 274.08M
Other diagnostic2024: 21.64M 2025: 19.17M
Transfusional medicine2024: 676.23M 2025: 702.69M
Country of domicile2024: 457.67M 2025: 471.47M
Other countries2024: 1.76B 2025: 1.87B
Rest of European Union2024: 1.16B 2025: 1.35B
United States and Canada2024: 4.42B 2025: 4.80B
All other segments2024: 225.05M 2025: 274.08M
Bio supplies2024: 233.70M 2025: 173.70M
Biopharma2024: 6.65B 2025: 7.32B
Diagnostic2024: 697.86M 2025: 721.87M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.32%6.0M258.1M534.88K
2026-10-152.71%7.0M258.1M572.65K
2026-09-302.71%7.0M258.1M627.51K
2026-09-151.32%3.4M258.1M599.98K
2026-08-311.32%3.4M258.1M635.59K
2026-08-141.36%3.5M258.1M667.33K
2026-07-311.34%3.5M258.1M701.05K
2026-07-152.46%6.3M258.1M690.72K
2026-06-302.37%6.1M258.1M665.96K
2026-06-152.33%6.0M258.1M692.45K
2026-05-292.28%5.9M258.1M732.38K
2026-05-152.31%6.0M258.1M759.06K
2026-04-302.19%5.7M258.1M745.69K
2026-04-152.09%5.4M258.1M664.84K
2026-03-312.04%5.3M258.2M649.35K
2026-03-132.72%7.0M258.2M571.22K
2026-02-272.75%7.1M258.2M538.12K
2026-02-132.51%6.5M257.4M491.64K
2026-01-302.67%6.9M257.3M587.38K
2026-01-152.68%6.9M257.3M601.11K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.006.508.800.000.0000.000.000.990-0.0140.000
call2.005.507.806.6015.0220.000.000.959-0.0860.001
call3.004.506.800.0010.5650.000.000.927-0.0980.002
call4.003.505.800.008.0670.000.000.894-0.0990.002
call5.002.754.800.006.2420.000.000.857-0.0960.003
call6.001.603.801.854.9430.000.000.811-0.0890.004
call7.000.602.050.991.92950.000.000.752-0.0800.004
call8.000.051.450.402.0026320.000.663-0.0830.005
call9.000.001.100.152.2337080.000.546-0.0750.005
call10.000.000.100.100.7983470.000.172-0.0150.004
call11.000.000.750.051.2011.000.000.131-0.0190.003
call12.000.001.150.001.5120.000.000.110-0.0220.003
call13.000.001.150.001.7720.000.000.098-0.0230.002
call14.000.001.150.002.0030.000.000.089-0.0240.002
call15.000.001.150.002.2110.000.000.083-0.0260.002
call16.000.001.150.002.3980.000.000.078-0.0270.002
put1.000.000.050.007.5300.000.00-0.009-0.0130.000
put2.000.001.150.0013.1710.000.00-0.040-0.0870.001
put3.000.001.150.009.4560.000.00-0.072-0.0980.002
put4.000.001.150.007.2310.000.00-0.105-0.1000.002
put5.000.001.150.005.6700.000.00-0.142-0.0970.003
put6.000.001.150.104.41067.000.00-0.187-0.0900.004
put7.000.000.900.203.3414280.00-0.247-0.0800.004
put8.000.001.250.243.0424850.00-0.339-0.0810.005
put9.000.001.800.003.0130.000.00-0.453-0.0750.005
put10.000.202.652.283.3800.000.00-0.828-0.0160.003
put11.001.203.300.003.1740.000.00-0.870-0.0190.003
put12.002.204.800.004.5540.000.00-0.889-0.0210.003
put13.003.405.800.004.9170.000.00-0.902-0.0220.002
put14.004.206.800.005.2370.000.00-0.910-0.0240.002
put15.005.207.800.005.5230.000.00-0.917-0.0250.002
put16.006.208.400.004.9730.000.00-0.922-0.0250.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-30SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-18SEC
2026-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-15SEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-07SEC
2026-04-1720-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-03-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-24SEC
2026-02-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-26SEC
2026-02-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-26SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-12SCHEDULE 13G/ASEC
2026-01-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-08SEC
2025-12-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-16SEC
2025-11-12SCHEDULE 13G/ASEC
2025-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-04SEC
2025-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-29SEC
2025-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-07-30SEC
2025-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-07-29SEC
2025-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-07-29SEC
2025-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-11SEC
2025-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-05SEC
2025-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-05-12SEC
2025-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-05-06SEC
2025-05-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-05-02SEC
2025-04-1120-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2024-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BRANDES INVESTMENT PARTNERS, LP14.64%
Capital World Investors8.87%
Permian Investment Partners, LP7.64%
BANK OF AMERICA CORP /DE/2.54%
Black Creek Investment Management Inc.2.48%
MILLENNIUM MANAGEMENT LLC1.69%
Flat Footed LLC1.68%
Jupiter Topco LLC1.15%
ARMISTICE CAPITAL, LLC1.14%
MORGAN STANLEY1.03%

Funds

Fund% owned
New Perspective Fund5.44%
International Growth and Income Fund2.01%
Brandes International Small Cap Equity Fund1.86%
Brandes Small Cap Value Fund0.64%
Brandes International ETF0.35%
Brandes U.S. Small-Mid Cap Value ETF0.13%
International Growth and Income Fund0.04%
Brandes Global Equity Fund0.04%
ActivePassive International Equity ETF0.01%
Enterprise Mergers and Acquisitions Fund0.00%

OakChart. GRFS. Cached 15 minutes.

Some panels did not load: insider.